昨天（12月27日），中核集团核技术医学转化与临床应用大会在核工业总医院/苏大附二院浒关院 区举行，总医院浒关二期正式投用。中国核工业集团有限公司总经理、党组副书记张涛，市委副书记、 市长吴庆文，苏州大学校长张桥出席活动。 中核集团总经济师、总审计师黄敏刚；苏州大学党委副书记、副校长沈明荣，市政府秘书长徐本， 苏州高新区和市有关部门主要负责同志等参加活动。 中核集团为我国核工业"国家队"和核技术应用产业链"链长"。2020年，集团与苏州市政府签署战略 合作协议，开启核特色医疗等领域合作新篇章。本次投用的总医院浒关二期是央地战略合作的重要成果 之一，聚焦核医疗及肿瘤、慢病等重点方向，着力打造集核技术精准诊疗中心、核技术临床试验中心、 核技术医学创新中心和核技术培训交流中心于一体的一流核医疗示范基地。 活动中，中核集团"核技术医学应用场景创新促进中心"在核工业总医院揭牌。该中心将充分融合苏 州区域生物医药产业优势和中核集团的研发能力、技术优势，开放核医疗场景资源，建设放射性药物和 高端核医疗装备应用的集成式场景。现场，中核粒子与核工业总医院首个战略合作实践成果"SPECT/CT 临床试验项目""IAEA肿瘤放射治 ...

Core Insights - Awei Technology (688067) announced an investment of 10 million yuan in Hunan Luying Technology Co., Ltd., acquiring a 9.0744% stake in the company [2] Group 1: Investment Details - The investment is aimed at enhancing the synergy of Awei Technology's main business and improving its overall competitiveness [2] - The core business of Luying Technology involves the development of domestically produced high-resolution single-photon emission computed tomography (SPECT) and its core components [2] Group 2: Strategic Significance - Awei Technology believes that this investment aligns with its long-term development plan and has positive strategic implications for its operations [2]

Core Viewpoint - Awei Technology (688067.SH) plans to invest a total of RMB 30 million in Luying Technology, acquiring a 9.0744% stake through a capital increase [1] Group 1: Investment Details - The investment will be made in partnership with state-owned investment institutions, including Guangzhou Guangjin Life Health Industry Investment Fund and Hunan Xiangjiang New Area Guidance No. 1 Venture Capital Partnership [1] - Awei Technology will contribute RMB 10 million, which will allow it to subscribe to RMB 249.3766 million of the new registered capital of Luying Technology [1] - The capital increase agreement has been signed among the investment parties and existing shareholders of Luying Technology [1] Group 2: Company Profile - Luying Technology, registered in Changsha, Hunan Province, has a registered capital of RMB 20 million [1] - The company specializes in the development of domestically produced high-resolution single-photon emission computed tomography (SPECT) and its core components [1] - Luying Technology provides hospitals with precise, safe, economical, and convenient molecular imaging diagnostic solutions, focusing on high-end nuclear medicine imaging and treatment equipment [1]

Core Viewpoint - Awei Technology (688067.SH) plans to invest a total of RMB 30 million in Luying Technology, acquiring a 9.0744% stake through a capital increase [1] Group 1: Investment Details - The investment will be made in partnership with state-owned investment institutions, including Guangzhou Guangjin Life Health Industry Investment Fund and Hunan Xiangjiang New Area Guidance No. 1 Venture Capital Partnership [1] - Awei Technology will contribute RMB 10 million, which will allow it to subscribe for RMB 2.493766 million of the new registered capital of Luying Technology [1] - The capital increase agreement has been signed among the investment parties and existing shareholders of Luying Technology [1] Group 2: Company Profile - Luying Technology, registered in Changsha, Hunan Province, has a registered capital of RMB 20 million [1] - The company specializes in the development of domestically produced high-resolution single-photon emission computed tomography (SPECT) and its core components [1] - Luying Technology provides hospitals with precise, safe, economical, and convenient molecular imaging diagnostic solutions, focusing on high-end nuclear medicine imaging and treatment equipment [1]